par AlGhamdi, Hamza;Dhont, Jennifer;Krayem, Mohammad ;De Bruyn, Pauline;Engels, Benedikt;Van Gestel, Dirk ;Van den Begin, Robbe
Référence Cancers (Basel), 14, 8
Publication Publié, 2022-04-01
Référence Cancers (Basel), 14, 8
Publication Publié, 2022-04-01
Article révisé par les pairs
Résumé : | Over the last years, the oligometastatic disease state has gained more and more interest, and randomized trials are now suggesting an added value of stereotactic radiotherapy on all macroscopic disease in oligometastatic patients; but what barriers could impede widespread disease in some patients? In this review, we first discuss the concept of oligometastatic disease and some examples of clinical evidence. We then explore the route to dissemination: the hurdles a tumoral clone has to overtake before it can produce efficient and widespread dissemination. The spectrum theory argues that the range of metastatic patterns encountered in the clinic is the consequence of gradually obtained metastatic abilities of the tumor cells. Tumor clones can obtain these capabilities by Darwinian evolution, hence early in their genetic progression tumors might produce only a limited number of metastases. We illustrate selective dissemination by discussing organ tropism, the preference of different cancer (sub)types to metastasize to certain organs. Finally we discuss biomarkers that may help to distinguish the oligometastatic state. |